Differentiated Therapeutics (dx/tx), a biotech company focused on computationally predicting and optimizing targeted protein degraders (TPDs), announced the completion of a $5 million Seed financing. Curie.Bio, a founder-focused seed-stage venture capital firm, financed the round.

Differentiated Therapeutics' mission is to design and develop disease-modifying TPD therapies for patients with unmet medical need. Founded in 2021 by leaders in small molecule and AI-driven drug discovery, the company is based in San Diego, CA and Cambridge, MA.